HRMY · Harmony Biosciences Holdings, Inc.
$38.12
-0.38 (-0.99%)
At close · Aug 14
Market Cap
$2.22B
Shares
58.24M
Harmony Biosciences Holdings, Inc. Earnings Call Transcripts
Every quarterly earnings call for Harmony Biosciences Holdings, Inc. (HRMY) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲45.2%
$117.21M
$87.94M
'22 Q3
22-11-01
▲40.7%
$128.31M
$48.51M
'22 Q4
23-02-21
▲39.6%
$119.13M
$29.48M
'23 Q1
23-05-02
▲25.4%
$134.22M
$34.30M
'23 Q2
23-08-01
▲36.7%
$160.27M
$38.46M
'23 Q3
23-10-31
▲31.3%
$168.41M
$26.61M
'23 Q4
24-02-22
▲29.8%
$154.62M
$38.33M
'24 Q1
24-04-30
▲28.8%
$172.81M
$11.59M
'24 Q2
24-08-06
▲16.1%
$186.04M
$46.09M
'24 Q3
24-10-29
▲19.5%
$201.27M
$49.48M
'24 Q4
25-01-13
▲19.5%
$184.73M
$45.56M
'25 Q1
25-05-06
▲16%
$200.49M
$39.78M
'25 Q2
25-08-05
▲28.7%
$239.46M
$50.87M
'25 Q3
25-11-04
▲21.1%
$243.78M
$22.49M
'25 Q4
26-02-24
▲16.6%
$215.39M
$32.49M
'26 Q1
26-05-07
LATEST
▲30.3%
$261.28M
$75.43M
'26 Q2
26-08-04
Earnings call
FY26 · Q2
2026-08-04
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
Confident tone
Phase 1 PK and safety data for BP-205
WAKIX commercial performance and revenue growth
Upcoming data catalysts
Revenue
$261.28M
▲ 30.3% YoY Diluted EPS
$1.28
▲ 88.2% YoY Gross margin
75.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Harmony Biosciences Holdings, Inc. Q1 FY2026 Earnings Call
Revenue
$215.39M
▲ 16.6% YoY Diluted EPS
$0.55
▼ 29.5% YoY Gross margin
79.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-04-13
25th Annual Needham Virtual Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-24
Harmony Biosciences Holdings, Inc. Q4 FY2025 Earnings Call
Confident tone
Late-stage pipeline and clinical catalysts
WAKIX commercial performance and blockbuster guidance
Pediatric narcolepsy approval and expansion
Revenue
$243.78M*
▲ 21.1% YoY Gross margin
71.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Harmony Biosciences Holdings, Inc. Q3 FY2025 Earnings Call
Confident tone
Pitolisant HD next-gen formulation
WAKIX commercial momentum
Pipeline setbacks and confidence
Revenue
$239.46M
▲ 28.7% YoY Diluted EPS
$0.87
▲ 10.1% YoY Gross margin
75.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Harmony Biosciences Holdings, Inc. Q2 FY2025 Earnings Call
Confident tone
Pipeline and late-stage catalysts
WAKIX commercial performance
Fragile X / ZYN002 opportunity
Revenue
$200.49M
▲ 16% YoY Diluted EPS
$0.68
▲ 240% YoY Gross margin
81.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Harmony Biosciences Holdings, Inc. Q1 FY2025 Earnings Call
Confident tone
WAKIX commercial performance in narcolepsy
ZYN002 in Fragile X Syndrome (RECONNECT)
Pitolisant HD next-generation formulation
Revenue
$184.73M
▲ 19.5% YoY Diluted EPS
$0.78
▲ 16.4% YoY Gross margin
82.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Harmony Biosciences Holdings, Inc. Q4 FY2024 Earnings Call
Confident tone
Pitolisant HD (next-generation) development
ZYN002 Fragile X program
Idiopathic Hypersomnia (IH) sNDA setback
Revenue
$201.27M*
▲ 19.5% YoY Gross margin
73.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-29
Harmony Biosciences Holdings, Inc. Q3 FY2024 Earnings Call
Confident tone
Rare epilepsy franchise (EPX-100, EPX-200)
Pitolisant franchise lifecycle (IH, GR, HD)
Late-stage pipeline and launches
Revenue
$186.04M
▲ 16.1% YoY Diluted EPS
$0.79
▲ 25.4% YoY Gross margin
77.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Harmony Biosciences Holdings, Inc. Q2 FY2024 Earnings Call
Confident tone
WAKIX commercial performance
Pediatric narcolepsy launch
Pitolisant HD / life-cycle management
Revenue
$172.81M
▲ 28.8% YoY Diluted EPS
$0.20
▼ 64.3% YoY Gross margin
81.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-30
Harmony Biosciences Holdings, Inc. Q1 FY2024 Earnings Call
Confident tone
TPM-1116 orexin-2 receptor agonist
WAKIX commercial performance
Pitolisant life cycle management & new indications
Revenue
$154.62M
▲ 29.8% YoY Diluted EPS
$0.67
▲ 39.6% YoY Gross margin
82.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Harmony Biosciences Holdings, Inc. Q4 FY2023 Earnings Call
Confident tone
WAKIX commercial growth and durability
Next-generation pitolisant formulations
Pediatric narcolepsy sNDA and pediatric exclusivity
Revenue
$168.41M*
▲ 31.3% YoY Gross margin
74.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-31
Harmony Biosciences Holdings, Inc. Q3 FY2023 Earnings Call
Revenue
$160.27M
▲ 36.7% YoY Diluted EPS
$0.63
▼ 56.2% YoY Gross margin
79.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Harmony Biosciences Holdings, Inc. Q2 FY2023 Earnings Call
Revenue
$134.22M
▲ 25.4% YoY Diluted EPS
$0.56
▲ 43.6% YoY Gross margin
81.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Harmony Biosciences Holdings, Inc. Q1 FY2023 Earnings Call
Revenue
$119.13M
▲ 39.6% YoY Diluted EPS
$0.48
▲ 37.1% YoY Gross margin
82.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-21
Harmony Biosciences Holdings, Inc. Q4 FY2022 Earnings Call
Revenue
$128.31M*
▲ 40.7% YoY Gross margin
79.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Harmony Biosciences Holdings, Inc. Q3 FY2022 Earnings Call
Revenue
$117.21M
▲ 45.2% YoY Diluted EPS
$1.44
Gross margin
80.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Harmony Biosciences Holdings, Inc. Q2 FY2022 Earnings Call
Revenue
$107.03M
▲ 45% YoY Diluted EPS
$0.39
▲ 62.5% YoY Gross margin
82.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Harmony Biosciences Holdings, Inc. Q1 FY2022 Earnings Call
Revenue
$85.31M
▲ 43% YoY Diluted EPS
$0.35
▲ 169.2% YoY Gross margin
82.8%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Harmony Biosciences Holdings, Inc. Q4 FY2021 Earnings Call
Revenue
$91.21M*
▲ 62% YoY Gross margin
80.5%
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Harmony Biosciences Holdings, Inc. Q3 FY2021 Earnings Call
Revenue
$80.73M
▲ 77% YoY Diluted EPS
$-0.17
Gross margin
81.9%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
Harmony Biosciences Holdings, Inc. Q2 FY2021 Earnings Call
Revenue
$73.82M
▲ 94.2% YoY Diluted EPS
$0.24
Gross margin
82.8%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Harmony Biosciences Holdings, Inc. Q1 FY2021 Earnings Call
Revenue
$59.67M
▲ 200.8% YoY Diluted EPS
$0.13
Gross margin
82.6%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-25
Harmony Biosciences Holdings, Inc. Q4 FY2020 Earnings Call
Revenue
$56.29M*
Gross margin
82.4%
Rev · 3q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-12
Harmony Biosciences Holdings, Inc. Q3 FY2020 Earnings Call
Revenue
$45.61M
Diluted EPS
$-0.14
Gross margin
82.7%
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Showing 1–26 of 26 earnings calls
Key facts
CIK
1802665
CUSIP
413197104
13F (30d)
303 filings
297 filers
Visit website
Investor relations